Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
The historical rank and industry rank for Beroni Group's EV-to-EBIT or its related term are showing as below:
FRA:6B9's EV-to-EBIT is not ranked *
in the Drug Manufacturers industry.
Industry Median: 15.84 * Ranked among companies with meaningful EV-to-EBIT only.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Beroni Group's Enterprise Value for the quarter that ended in Jun. 2024 was €0.00 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beroni Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-3.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beroni Group EV-to-EBIT Related Terms
Beroni Group EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Beroni Group's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6B9 vs PNXP, CRYM, GCAN: EV-to-EBIT Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Beroni Group's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beroni Group EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beroni Group's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Beroni Group's EV-to-EBIT falls into.
Beroni Group's current Enterprise Value is €-0.30 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Beroni Group's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was €-3.71 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beroni Group (FRA:6B9) has a EV-to-EBIT of 0.08 as of Sep. 15, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Beroni Group and its competitors.
Is Beroni Group's EV-to-EBIT too high?
Beroni Group's current EV-to-EBIT is 0.08. The Drug Manufacturers industry median EV-to-EBIT is 15.84. Beroni Group's value of 0.08 is 99.5% below this industry median. Overall, Beroni Group has a GF Score™ of 57/100, reflecting its overall financial health beyond just this single metric.
How does Beroni Group's EV-to-EBIT compare to PNXP and CRYM?
Beroni Group's EV-to-EBIT of 0.08 can be compared against companies in the Drug Manufacturers industry. The industry median EV-to-EBIT is 15.84. Beroni Group's value of 0.08 is 99.5% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.84, based on 684 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beroni Group's current EV-to-EBIT of 0.08 is 99.5% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Beroni Group and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beroni Group's current EV-to-EBIT is 0.08. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beroni Group stock overvalued right now?
Beroni Group (FRA:6B9) has a current EV-to-EBIT of 0.08. The current EV-to-EBIT is 0.08 and 99.5% below the Drug Manufacturers industry median of 15.84. Beroni Group's overall GF Score™ is 57/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Beroni Group (FRA:6B9), the current EV-to-EBIT is 0.08 as of Sep. 15, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beroni Group Ltd is an Australia based company engaged in the sales of smoking control product (NicoBloc), air purifier, water filter, healthcare products and supplements, cell therapies, stem-cell based cosmetics and viral diagnostic kits and also investing in the research and development of oncology drugs and therapies. It has organized its business into four core business areas: cell therapies, developing new anticancer drugs, an e-commerce platform for pharmaceutical and healthcare products, and detection & diagnosis of infectious diseases. Geographically, the company operates in China.
57GF Score
Get the complete analysis for FRA:6B9
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6B9 has been successfully added to your 
